Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
This study has been completed.
Study NCT00257855   Information provided by University College London Hospitals
First Received: November 22, 2005   Last Updated: February 12, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Neoplasm Metastasis
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Neoplasms
Neoplastic Processes
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Lamotrigine
More general drug interventions related to this trial
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University College London Hospitals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services